Propel Bio Management, LLC Delcath Systems, Inc. Transaction History
Propel Bio Management, LLC
- $101 Billion
- Q4 2024
A detailed history of Propel Bio Management, LLC transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 17,000 shares of DCTH stock, worth $270,640. This represents 0.2% of its overall portfolio holdings.
Number of Shares
17,000Holding current value
$270,640% of portfolio
0.2%Shares
1 transactions
Others Institutions Holding DCTH
# of Institutions
95Shares Held
11MCall Options Held
144KPut Options Held
57.4K-
Vivo Capital, LLC Palo Alto, CA1.71MShares$27.2 Million3.93% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.39MShares$22.1 Million6.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.22MShares$19.5 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT801KShares$12.8 Million0.66% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY612KShares$9.75 Million0.08% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $137M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...